EIF3K抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: HT29 cell lysate, Primary antibody: P10054(EIF3K Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10054(EIF3K Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The eukaryotic translation initiation factor 3 subunit K (EIF3K) is a component of the EIF3 complex, a critical regulator of protein synthesis in eukaryotic cells. EIF3. comprising 13 subunits (EIF3A to EIF3M), plays a central role in initiating mRNA translation by recruiting ribosomes and facilitating the assembly of the 43S pre-initiation complex. EIF3K, a conserved 24-kDa protein encoded by the *EIF3K* gene, interacts with other EIF3 subunits (e.g., EIF3D) to stabilize the complex and modulate its activity. Beyond its canonical role in translation, EIF3K has been implicated in cellular processes such as apoptosis, cell cycle regulation, and stress response. Dysregulation of EIF3K expression is linked to pathologies, including cancers (e.g., colorectal, liver) and neurodegenerative disorders, highlighting its potential as a diagnostic or therapeutic target.

Antibodies against EIF3K are essential tools for studying its expression, localization, and interactions. They enable detection via Western blotting, immunofluorescence, and immunohistochemistry in diverse biological samples. Validated EIF3K antibodies are crucial for distinguishing its role in normal versus diseased states, particularly in translational control mechanisms. Specificity is confirmed using knockdown/knockout controls or immunoprecipitation assays. Research using these antibodies has uncovered EIF3K’s involvement in mTOR signaling and its regulatory effects on oncogenic pathways. Commercially available antibodies (e.g., from Sigma-Aldrich, Abcam) often include recombinant protein-validated options, ensuring reliability in experimental workflows.